Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pardes Biosciences, Inc. (PRDS : NSDQ)

• Company Description    Pardes Biosciences Inc. is a clinical-stage biopharmaceutical company. It discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company's lead product candidate includes PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences Inc., formerly known as FS Development Corp. II, is based in SAN FRANCISCO, Calif. Number of Employees: 30

• Price / Volume Information    Yesterday's Closing Price: $5.69 Daily Weekly Monthly 20 Day Moving Average: 163,138 shares Shares Outstanding: 62.38 (millions) Market Capitalization: $354.94 (millions) Beta: 1.09 52 Week High: $17.76 52 Week Low: $4.89 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -27.15% -20.17% 12 Week -39.98% -34.87% Year To Date -65.24% -58.67%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2173 SALK AVENUE SUITE 250 - CARLSBAD,CA 92008 USA ph: 415-649-8758 fax: - None None

• General Corporate Information    Officers Thomas G. Wiggans - Chief Executive Officer and Chairman Heidi Henson - Chief Financial Officer Mark Auerbach - Director Deborah M. Autor - Director Laura J. Hamill - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 69945Q105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 62.38 Most Recent Split Date: (:1) Beta: 1.09 Market Capitalization: $354.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.39 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.72 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.44 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -43.59 12/31/21 - -57.63 09/30/21 - - ROA 03/31/22 - -23.73 12/31/21 - -17.46 09/30/21 - - Current Ratio 03/31/22 - 29.12 12/31/21 - 30.70 09/30/21 - 0.23 Quick Ratio 03/31/22 - 29.12 12/31/21 - 30.70 09/30/21 - 0.23 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 3.95 12/31/21 - 4.69 09/30/21 - -0.43 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - - Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - -

Powered by Zacks Investment Research ©